The United States of America, As Represented by the Secretary, Department of Health and Human Services

The Ohio State University

The United States of America As Represented by the Department of Health

The United States of America As Represented by the Secretary of

Other

University of Dundee

Masaryk Memorial Cancer Institute

Johns Hopkins University

Nestec S.a.

The United States of America

Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Vojtesek, Borivoj

The Government of the United States of America As Represented by the Secretary of the Department of

Curtis C Harris

Carlo M Croce

Makoto Nagashima

Xin Wei Wang

Aaron J Schetter

John F Lechner

Frank J Gonzalez

Roger R Reddel

Andrea M Pfeifer

Albert J Fornace, Jr

Katharine H Cole

Jill D Coursen

Qimin Zhan

Harry V Gelboin

David Philip Lane

Borivoj Vojtesek

Jean-Christophe Bourdon

Jan H J Hoeijmakers

Izumi Horikawa

Nozomu Yanaihara

Kaori Fujita

James Gordon Herman

Kristopher W Krausz

Johng S Rhim

Andrew D Patterson

Douglas E Brash

Remy Pedeux

Robert T Su

Qin Yang

Brenda I Gerwin

Paul Amstad

Katharine C Mace

Majda Haznadar

Masayuki Shiseki

Hirohide Yoshikawa

Ewy Mathe

Soumen Manna

David P Lane

Brent E Korba

Chandrakant P Giri

George H Yoakum

Masahiro Seike

Aaron Joseph Schetter

Hirokazu Okayama

Yang Ke

James C Willey

Ichiro Akagi

Hiroyasu Ogawa

Jan H Hoeijmakers

Robert Yolken

Ih-Chang Hsu

Ke Yang

Manuel Serrano

Kye-Yoon Park

Sharon R Pine

Abdul M Mondal

The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

Method for the diagnosis and prognosis of cancer

The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

The invention provides novel biomarkers (four genes BRCA1, HIF1A, DLC1, and XPO1 alone or in combination of miR-21) for early stage lung cancer.

Expression protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer

The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.

Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer

Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-&#x3b3; and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-&#x3b3; and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.

Methods of determining the prognosis of an adenocarcinoma

Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer

The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.

Tumor suppressor gene p47ING3

The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

Method of diagnosing poor survival prognosis colon cancer using miR-16b

The present invention provides methods and compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.

POT1 alternative splicing variants

Tumor suppressor gene, p47ING3

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents.

MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P

MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21

Method of diagnosing poor survival prognosis colon cancer using let-7g

Method of diagnosing poor survival prognosis colon cancer using miR-10a

Growing community of inventors

Garrett Park, MD, United States of America

Curtis C Harris